

**Brilliant Violet 605™ anti-mouse CD127 (IL-7Rα)**

**Catalog # / Size:** 1275125 / 125 μl  
1275205 / 50 μg

**Clone:** A7R34

**Isotype:** Rat IgG2a, κ


**Immunogen:** IL-7Ra-IgG1 fusion protein

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** microg size: 0.2 mg/ml  
test size: lot-specific




C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD127 (clone A7R34) Brilliant Violet 605™ (top) or rat IgG2a, κ Brilliant Violet 605™ isotype control (bottom).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the microg size, the suggested use of this reagent is 0.6 microg per million cells in 100 microL volume. For flow cytometric staining using the test size, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The

purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** A7R34 is able to block clone SB/199 binding to IL-7R.

**Application References:**

1. Sudo T, *et al.* 1993. *P. Natl. Acad. Sci. USA* 90:9125.
2. Hashi H, *et al.* 2001. *J. Immunol.* 166:3702.
3. Taylor R, *et al.* 2007. *J. Immunol.* 178:5659.
4. Mazzon C, *et al.* 2011. *Blood.* 118:2733. [PubMed](#)
5. Jin J, *et al.* 2011. *J. Immunol.* doi:10.4049/jimmunol.1001238. [PubMed](#)

---

**Description:** CD127 is a 60-90 kD type I transmembrane glycoprotein also known as IL-7 receptor  $\alpha$  chain or IL-7R $\alpha$ . It forms a heterodimer with the common  $\gamma$  chain ( $\gamma$ c or CD132) which is shared with the receptors for IL-2, IL-4, IL-9, IL-13, IL-15, and IL-21. CD127 is expressed on immature B cells through early pre-B stage, thymocytes (except CD4/CD8 double positive thymocytes), peripheral T cells, and bone marrow stromal cells. CD127 has been reported to be a useful marker for identifying memory and effector T cells. The ligation of IL-7 with its receptor is important for stimulation of mature and immature T cells as well as immature B cells proliferation and development.

**Antigen References:**

1. Sudo T, *et al.* 1993. *P. Natl. Acad. Sci. USA* 90:9125.
2. Okuno Y, *et al.* 2001. *P. Natl. Acad. Sci. USA* 99:6246.
3. Pillai M, *et al.* 2004. *Leukemia Lymphoma* 45:2403.